209 related articles for article (PubMed ID: 21540640)
1. Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer.
Yeh KT; Chen TH; Yang HW; Chou JL; Chen LY; Yeh CM; Chen YH; Lin RI; Su HY; Chen GC; Deatherage DE; Huang YW; Yan PS; Lin HJ; Nephew KP; Huang TH; Lai HC; Chan MW
Epigenetics; 2011 Jun; 6(6):727-39. PubMed ID: 21540640
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.
Chou JL; Su HY; Chen LY; Liao YP; Hartman-Frey C; Lai YH; Yang HW; Deatherage DE; Kuo CT; Huang YW; Yan PS; Hsiao SH; Tai CK; Lin HJ; Davuluri RV; Chao TK; Nephew KP; Huang TH; Lai HC; Chan MW
Lab Invest; 2010 Mar; 90(3):414-25. PubMed ID: 20065949
[TBL] [Abstract][Full Text] [Related]
3. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Kikuchi R; Tsuda H; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2007 Aug; 67(15):7095-105. PubMed ID: 17671176
[TBL] [Abstract][Full Text] [Related]
4. Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21.
Derks S; Bosch LJ; Niessen HE; Moerkerk PT; van den Bosch SM; Carvalho B; Mongera S; Voncken JW; Meijer GA; de Bruïne AP; Herman JG; van Engeland M
Carcinogenesis; 2009 Jun; 30(6):1041-8. PubMed ID: 19329758
[TBL] [Abstract][Full Text] [Related]
5. ChIP-seq defined genome-wide map of TGFβ/SMAD4 targets: implications with clinical outcome of ovarian cancer.
Kennedy BA; Deatherage DE; Gu F; Tang B; Chan MW; Nephew KP; Huang TH; Jin VX
PLoS One; 2011; 6(7):e22606. PubMed ID: 21799915
[TBL] [Abstract][Full Text] [Related]
6. DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-β/SMAD4 signaling.
Chan DW; Hui WW; Wang JJ; Yung MM; Hui LM; Qin Y; Liang RR; Leung TH; Xu D; Chan KK; Yao KM; Tsang BK; Ngan HY
Oncogene; 2017 Mar; 36(10):1404-1416. PubMed ID: 27593933
[TBL] [Abstract][Full Text] [Related]
7. Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis.
Hinshelwood RA; Huschtscha LI; Melki J; Stirzaker C; Abdipranoto A; Vissel B; Ravasi T; Wells CA; Hume DA; Reddel RR; Clark SJ
Cancer Res; 2007 Dec; 67(24):11517-27. PubMed ID: 18089780
[TBL] [Abstract][Full Text] [Related]
8. Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer.
Chan MW; Huang YW; Hartman-Frey C; Kuo CT; Deatherage D; Qin H; Cheng AS; Yan PS; Davuluri RV; Huang TH; Nephew KP; Lin HJ
Neoplasia; 2008 Sep; 10(9):908-19. PubMed ID: 18714391
[TBL] [Abstract][Full Text] [Related]
9. Histone modifications silence the GATA transcription factor genes in ovarian cancer.
Caslini C; Capo-chichi CD; Roland IH; Nicolas E; Yeung AT; Xu XX
Oncogene; 2006 Aug; 25(39):5446-61. PubMed ID: 16607277
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers.
Huang RL; Gu F; Kirma NB; Ruan J; Chen CL; Wang HC; Liao YP; Chang CC; Yu MH; Pilrose JM; Thompson IM; Huang HC; Huang TH; Lai HC; Nephew KP
Epigenetics; 2013 Jun; 8(6):624-34. PubMed ID: 23774800
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation and decreased expression of the TGF-β/Smad target gene FBXO32 in esophageal squamous cell carcinoma.
Guo W; Zhang M; Shen S; Guo Y; Kuang G; Yang Z; Dong Z
Cancer; 2014 Aug; 120(16):2412-23. PubMed ID: 24798237
[TBL] [Abstract][Full Text] [Related]
12. Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications.
Kwon MJ; Kim SS; Choi YL; Jung HS; Balch C; Kim SH; Song YS; Marquez VE; Nephew KP; Shin YK
Carcinogenesis; 2010 Jun; 31(6):974-83. PubMed ID: 20053926
[TBL] [Abstract][Full Text] [Related]
13. A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.
Fu L; Shi J; Liu A; Zhou L; Jiang M; Fu H; Xu K; Li D; Deng A; Zhang Q; Pang Y; Guo Y; Hu K; Zhou J; Wang Y; Huang W; Jing Y; Dou L; Wang L; Xu K; Ke X; Nervi C; Li Y; Yu L
Int J Cancer; 2017 Feb; 140(3):653-661. PubMed ID: 27770540
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
[TBL] [Abstract][Full Text] [Related]
15. Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer.
Kikuchi R; Tsuda H; Kozaki K; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2008 Jul; 68(13):5067-75. PubMed ID: 18593905
[TBL] [Abstract][Full Text] [Related]
16. TGF-β: friend or foe? The role of TGF-β/SMAD signaling in epigenetic silencing of ovarian cancer and its implication in epigenetic therapy.
Chou JL; Chen LY; Lai HC; Chan MW
Expert Opin Ther Targets; 2010 Nov; 14(11):1213-23. PubMed ID: 20925461
[TBL] [Abstract][Full Text] [Related]
17. Ras-induced epigenetic inactivation of the RRAD (Ras-related associated with diabetes) gene promotes glucose uptake in a human ovarian cancer model.
Wang Y; Li G; Mao F; Li X; Liu Q; Chen L; Lv L; Wang X; Wu J; Dai W; Wang G; Zhao E; Tang KF; Sun ZS
J Biol Chem; 2014 May; 289(20):14225-38. PubMed ID: 24648519
[TBL] [Abstract][Full Text] [Related]
18. DNA demethylation is superior to histone acetylation for reactivating cancer-associated genes in ovarian cancer cells.
Meng CF; Su B; Li W
Mol Med Rep; 2011; 4(6):1273-8. PubMed ID: 21850374
[TBL] [Abstract][Full Text] [Related]
19. Towards sustained silencing of HER2/neu in cancer by epigenetic editing.
Falahi F; Huisman C; Kazemier HG; van der Vlies P; Kok K; Hospers GA; Rots MG
Mol Cancer Res; 2013 Sep; 11(9):1029-39. PubMed ID: 23814024
[TBL] [Abstract][Full Text] [Related]
20. TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer.
Wang N; Zhang H; Yao Q; Wang Y; Dai S; Yang X
J Exp Clin Cancer Res; 2012 Jan; 31(1):6. PubMed ID: 22248469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
